Changes in Serum S100A12 and sRAGE Associated with Improvement of the PaO&lt;sub&gt;2&lt;/sub&gt;/FiO&lt;sub&gt;2&lt;/sub&gt; Ratio following PMX-DHP Therapy for Postoperative Septic Shock

Takahashi, Goro; Hoshikawa, Koichi; Matsumoto, Naoya; Shozushima, Tatsuyori; Onodera, Chiaki; Kan, Shigenori; Akitomi, Shinji; Kikkawa, Tomohiro; Y, Tomisawa; Kojika, Masahiro; Sato, Nobuhiro; Inoue, Yasuhiro; Suzuki, Kenji; Wakabayashi, Go; Endo, Shunsuke

doi:10.1159/000330448

Cited by 11 publications

(8 citation statements)

References 53 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that elevated sputum levels may be useful to assess eosinophilic asthma [284]. High concentrations of MMP-7, ICAM-1, IL-8, VCAM-1, and S100A12 predicted poor overall survival of patients with idiopathic pulmonary fibrosis [352] and S100A12 is useful as an early marker of acute, early-stage lung injury in patients with sepsis [353,354]. …”

Section: S100 Proteins As Disease Markersmentioning

confidence: 99%

Functions of S100 Proteins

Donato¹,

Cannon²,

Sorci³

et al. 2013

Current Molecular Medicine

1,089

709

View full text Add to dashboard Cite

The S100 protein family consists of 24 members functionally distributed into three main subgroups: those that only exert intracellular regulatory effects, those with intracellular and extracellular functions and those which mainly exert extracellular regulatory effects. S100 proteins are only expressed in vertebrates and show cell-specific expression patterns. In some instances, a particular S100 protein can be induced in pathological circumstances in a cell type that does not express it in normal physiological conditions. Within cells, S100 proteins are involved in aspects of regulation of proliferation, differentiation, apoptosis, Ca2+ homeostasis, energy metabolism, inflammation and migration/invasion through interactions with a variety of target proteins including enzymes, cytoskeletal subunits, receptors, transcription factors and nucleic acids. Some S100 proteins are secreted or released and regulate cell functions in an autocrine and paracrine manner via activation of surface receptors (e.g. the receptor for advanced glycation end-products and toll-like receptor 4), G-protein-coupled receptors, scavenger receptors, or heparan sulfate proteoglycans and N-glycans. Extracellular S100A4 and S100B also interact with epidermal growth factor and basic fibroblast growth factor, respectively, thereby enhancing the activity of the corresponding receptors. Thus, extracellular S100 proteins exert regulatory activities on monocytes/macrophages/microglia, neutrophils, lymphocytes, mast cells, articular chondrocytes, endothelial and vascular smooth muscle cells, neurons, astrocytes, Schwann cells, epithelial cells, myoblasts and cardiomyocytes, thereby participating in innate and adaptive immune responses, cell migration and chemotaxis, tissue development and repair, and leukocyte and tumor cell invasion.

show abstract

Section: S100 Proteins As Disease Markersmentioning

confidence: 99%

Functions of S100 Proteins

Donato¹,

Cannon²,

Sorci³

et al. 2013

Current Molecular Medicine

1,089

709

View full text Add to dashboard Cite

show abstract

“…We recorded the positive dynamics of the oxygenation index while assessing oxygenic pulmonary function in the context of PMX hemoperfusion. In our opinion, the impact of this hemocorrection method on pulmonary function is based on the reduction in the endothelial permeability of pulmonary vessels, suppression of nitric oxide production, and decrease in monocyte activity and sequestration and aggressive molecules of the inflammatory cascade [13, 31, 32].…”

Section: Discussionmentioning

confidence: 99%

Selective Polymyxin Hemoperfusion in Complex Therapy of Sepsis in Children after Cardiac Surgery

et al. 2020

View full text Add to dashboard Cite

Background: To date, sepsis remains one of the main challenges of intensive care in pediatrics. Newborns with low birth weight and infants with chronic diseases and congenital disorders are particularly at risk. The incidence of infectious complications in pediatric cardiac surgery is known to be approximately 15–30%. The main etiological factor of sepsis is endotoxin. Aim: To evaluate the efficiency and safety of polymyxin (PMX) B-immobilized column-direct hemoperfusion in complex intensive therapy of sepsis in children after cardiac surgery with cardiopulmonary bypass. Design: Prospective cohort study. Methods: This study enrolled 15 children, aged 9–96 months, with congenital heart diseases and with body weights of 6.2–22.5 kg. The criteria for admission were body weight >6 kg and clinical and laboratory signs of sepsis (microbiological analysis, procalcitonin [PCT] >2 ng/mL, and endotoxin activity assay [ЕАА] >0.6). Intensive care included inotropic and vasopressor support, mechanical ventilation, broad-spectrum antibiotic therapy, and PMX hemoperfusion procedures. Extracorporeal therapy was initiated within 24 h following the sepsis diagnosis. Every patient underwent 2 hemoperfusion sessions with the use of a PMX B-immobilized column; the session duration was 180 min. Results: We noted improvements in hemodynamic parameters, oxygenation index, and laboratory signs of sepsis, with decreases in the endotoxin concentration according to the EAA, PCT, and presepsin levels. The 28-day survival of the patients in this severely affected group was 80%. Main Conclusion: The inclusion of extracorporeal methods of blood purification, aimed at the selective elimination of circulating endotoxin, in the treatment of sepsis increases the survival rates of children after open heart surgery. Second Conclusion: The obtained results of sepsis therapy with PMX hemoperfusion in children after cardiac surgery enable us to suggest the sufficient safety and efficiency of the procedures in this category of severely affected patients.

show abstract

“…The efficacy of hemoadsorption treatment in this case could probably be due to multiple mechanism of immunomodulation, not only endotoxin removal. Notably PMX-DHP reduces the concentration of pro-inflammatory and anti-inflammatory cytokines [8], high mobility group box protein 1 (HMGB-1) [9], and the receptor for advanced glycation end-products [10] decreasing in the excessive systemic host inflammatory response to infection.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Pyonephritis Complicated by Septic Shock Using Extracorporeal Device Polymyxin B-Hemoperfusion

et al. 2020

View full text Add to dashboard Cite

Direct hemoperfusion using polymyxin B-immobilized fiber (PMX-DHP) is an established treatment method for septic shock caused by Gram-negative infections. We report one instance in which PMX-DHP therapy has been used successfully in a 33-year-old woman with septic shock from urosepsis. Although there is lack of recommendations in latest Surviving Sepsis Campaign Guidelines, evidence of PMX-DHP efficacy in this subset of patients is growing.

show abstract

Changes in Serum S100A12 and sRAGE Associated with Improvement of the PaO<sub>2</sub>/FiO<sub>2</sub> Ratio following PMX-DHP Therapy for Postoperative Septic Shock

Cited by 11 publications

References 53 publications

Functions of S100 Proteins

Functions of S100 Proteins

Selective Polymyxin Hemoperfusion in Complex Therapy of Sepsis in Children after Cardiac Surgery

Treatment of Pyonephritis Complicated by Septic Shock Using Extracorporeal Device Polymyxin B-Hemoperfusion

Contact Info

Product

Resources

About